Therefore, PRSS1 and SPINK1 are potential combined adjuvant biomarkers for investigating the mechanisms underlying the increased risk of AP, and PRSS1 and SPINK1 should be considered as targets for drug therapy. This evidence concerns the gene PRSS1 and alkaline phosphatase measurement.